Phase 1bData readout

PLN-101095

Solid tumor/s, Cancer

PLRXPliant Therapeutics

Expected catalystDecember 31, 2027Company guidance: Dec 31, 2027

Catalyst overview

Event details

Drug or asset: PLN-101095
Development stage: Phase 1b
Event type: Data readout
Indication: Solid tumor/s, Cancer

Research summary

What is being tracked?

This catalyst tracks a Phase 1b data readout for PLN-101095 in Solid tumor/s, Cancer. The expected timing is based on the latest available company guidance and may change.

Development notes

08/11/26:- FORTIFY enrollment strong and ahead; interim Ph1b data expected in 2027. 08/18/26:- FDA Fast Track granted with pembrolizumab; FORTIFY NCT06270706 Phase 1a/1b data expected in 2027.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source